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Abstract: Fibroblast growth factor receptors (FGFRs) interact with their cognate ligands, 
FGFs, and with a number of cell adhesion molecules (CAMs), such as the neural cell 
adhesion molecule (NCAM), mediating a wide range of events during the development and 
maintenance of the nervous system. Determination of protein structure, in silico modeling 
and biological studies have recently resulted in the identification of FGFR binding peptides 
derived from various FGFs and NCAM mimicking the effects of these molecules with 
regard to their neuritogenic and neuroprotective properties. This review focuses on recently 
developed functional peptide agonists of FGFR with possible therapeutic potential. 
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1. Introduction 
1.1. FGF Receptors 
Fibroblast growth factors (FGFs) exert their effects in target cells by signaling through cell-surface 
receptor tyrosine kinases. Five FGF receptors (FGFRs), FGFR1-5, have been identified. FGFRs 
contain three extracellular immunoglobulin (Ig)-like modules, an acidic region located between Ig1 
and Ig2, a single transmembrane domain, and an intracellular split tyrosine kinase domain [1]. FGFR5 
does not contain an active tyrosine kinase domain. Alternative mRNA splicing results in a number of 
FGFR splice variants. The third Ig module of FGFR1-3 is encoded by the invariant exon IIIa followed 
by one of two alternative exons, IIIb or IIIc [2]. Alternate usage of exons IIIb or IIIc affects the 
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specificity of FGF binding to FGFRs. For example, FGF7 and FGF10 are known to bind FGFR2 IIIb 
but not FGFR2 IIIc [3,4]. 
Binding of FGFs to FGFRs induces FGFR dimerization, leading to receptor autophosphorylation 
[5]. Autophosphorylation of tyrosine residues in the intracellular domain of FGFR results in the 
docking of FGF receptor substrate 2 (FRS2), phospholipase-C (PLC), and Src homologous and 
collagenA (ShcA) and subsequent activation of various intracellular signaling pathways, including the 
mitogen-activated protein (MAP) kinase, calcium/calmodulin dependent protein kinase, and 
phosphoinositide-3 (PI3) kinase pathways [6,7].  
1.2. Ligands of FGF Receptors 
1.2.1. FGFs 
FGFs comprise a large family of 22 structurally and functionally related polypeptide growth factors. 
In vertebrates, the molecular mass of FGFs ranges from 17 to 34 kDa. FGFs possess a central core of 
140 amino acids containing 12 antiparallel -strands in which the sequence similarity between 
different members is 30-60% [8]. FGFs bind heparin and heparan sulfate proteoglycans with high 
affinity [9]. Several basic amino-acid residues in the 10-11 strands of the growth factors are 
supposed to be involved in heparin binding [10]. This interaction is hypothesized to be important for 
FGF stabilization and FGFR activation [11,12].  
Among the 22 FGF members, at least 10 are expressed in the brain. FGF1 is predominantly 
expressed in neurons and is involved in neuroprotection, learning, and memory. FGF2 is expressed in 
both neurons and astrocytes and is involved in neurogenesis, axonal growth, neuroprotection, and 
regeneration. FGF1 knockout mice are normal in appearance and behavior [13]. FGF2 knockout mice 
are viable but exhibit distinct defects in the organization of cortical neurons [14]. Our knowledge of 
the roles of other FGFs expressed in the central nervous system is currently limited [15]. FGF6 
knockout mice are viable, and they display only mild disturbances in muscle regeneration [16]. FGF8 
knockout is lethal and is characterized by mid-hindbrain boundary defects [17] and disturbed 
cerebellar development [18]. FGF8 is also required for the survival of nephrons [19]. FGF9 has been 
suggested to be a survival factor for medial thoracic and sacral motoneurons and retinal ganglion cells 
[20,21]. FGF17-deficient mice display disturbed cerebellar development [18]. 
1.2.2. Cell Adhesion Molecules 
In addition to the cognate ligands, the FGFs, FGFR interacts with a number of cell adhesion 
molecules (CAMs), including the neural cell adhesion molecule (NCAM), N-cadherin, L1, 
neurofascin, and neuroplastin [22-25]. NCAM, N-cadherin, and L1 all promote neuronal 
differentiation as reflected by neurite outgrowth following homophilic binding to the same CAM 
expressed on the responsive cell [26]. The possible involvement of FGFR in CAM-mediated induction 
of neuronal differentiation has been suggested by the observation that a specific tyrosine kinase 
inhibitor blocked the neurite outgrowth response to all three CAMs at an early stage in the signal 
transduction cascade. A so-called CAM homology domain in FGFR1 (i.e., a stretch of 20 amino acids 
residing in the IgII module) has been suggested to be involved in CAM binding [27-30]. This sequence Int. J. Mol. Sci. 2010, 11                 
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is highly conserved between all FGFRs and has sequence homology with N-cadherin, NCAM, and L1 
[29]. This review focuses primarily on NCAM interactions with FGFR because many of the FGFR 
peptide agonists have been derived from this molecule. 
NCAM plays multiple roles in nervous system development and maintenance [31-34]. NCAM also 
modulates neuronal plasticity, mediating learning and memory [35-37]. Studies in NCAM knockout 
mice show that NCAM is crucial for the formation of the olfactory bulb and the mossy fiber system in 
the hippocampus [38,39]. Polysialic acid (PSA) is a linear homopolymer containing 2, eight sialic 
acid residues, and NCAM has been shown to be the main PSA carrier in vertebrates. The 
polysialylated form of NCAM (PSA-NCAM) plays an important role in neural plasticity, including 
axonal growth, cell migration, synaptic plasticity, and embryonic and adult neurogenesis [40]. Slices 
prepared from either NCAM knockout mice or mice treated with a PSA-removing enzyme, Endo N, 
display defects in long-term potentiation (LTP) in the CA1 region of the hippocampus [41].  
NCAM is a member of the immunoglobulin (Ig) superfamily (IgSF) and was first described as a 
synaptosomal membrane protein, termed D2 [42]. NCAM is widely expressed in the developing 
nervous system and is also found in muscles, heart, kidneys, and gonads. The extracellular part of 
NCAM is composed of five Ig modules (Ig1-Ig5) and two fibronectin type III (FN3) modules, FN3(1) 
and FN3(2). In the nervous system three major isoforms are expressed, NCAM-120, NCAM-140, and 
NCAM-180 (the numbers corresponding to their relative molecular weights), resulting from alternative 
splicing of a single gene. NCAM-140 and NCAM-180 are transmembrane isoforms that differ in the 
size of their cytoplasmic domains, whereas NCAM-120 is attached to the membrane via a 
glycosylphosphatidylinositol (GPI) anchor lacking the cytoplasmic domains [43]. By means of nuclear 
magnetic resonance (NMR) spectroscopy and X-ray crystallography, the structures of the NCAM   
Ig1-3, FN3(1), and FN3(2) modules have been determined [44-46]. 
Direct binding of the two NCAM FN3 modules to the second and third FGFR1 Ig modules has been 
demonstrated by surface plasmon resonance (SPR) analysis [45]. The NCAM FN3 modules can mimic 
the neuritogenic activity of the intact molecule [47,48], presumably via interactions with FGFR. 
Moreover, the second NCAM FN3 module has been shown to induce FGFR1 phosphorylation and 
promote neurite outgrowth in an FGFR activation-dependent fashion. An NCAM binding site for 
FGFR1 has been mapped by NMR titration analysis to a region in the second FN3 module [45]. This 
region also has sequence and structural homology with a part of FGF2. 
2. Peptide Agonists of FGFR Derived from FGFs 
During the past few years, several peptide agonists of FGFR have been identified based on analyses 
of the interaction interfaces between FGFs and FGFRs as they appear in the crystal structure of the 
FGF-FGFR complexes. Other FGFR binding peptides have been identified based on analyses of 
sequence and structure homologies between FGFs and CAMs. 
2.1. Canofins: Peptide Agonists of FGFR Derived from the Canonical FGFR Binding Sites 
According to the crystal structure of the FGF2-FGFR1c complexes, FGF2 forms contacts with Ig2, 
Ig3, and the interconnecting linker of FGFR1c. The FGF2 residues involved in interactions with Ig2 of 
the receptor have been shown to be located in the 1, 2, 3, and 12 strands and in the 1-2 and  Int. J. Mol. Sci. 2010, 11                 
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8-9 loops. The FGF2 residues located in the N-terminus, the 4, 5, and 8 strands, and the 7-8 
loop are involved in interactions with Ig3. The FGF2 residues interacting with the Ig2-Ig3 linker 
interface are located in the 8-9 loop and 9 strand [49]. All binding interfaces with FGFR1c are 
generally located on one side of the FGF2 globular structure (Figure 1, yellow). 
Figure 1. A space-filling model of FGF2 (PDB:1CVS). Two 180 rotation projections are 
shown. The sequence motifs of hexafin and dekafin are mapped in red and magenta, 
respectively. The residues constituting the primary and secondary FGFR binding sites [49] 
are shown in yellow. The figure was made using PyMOL Molecular Viewer (DeLano 
Scientific LLC, San Francisco, CA, USA). 
 
 
Three peptides, termed canofin1, canofin2, and canofin3, have been derived from the canonical 
binding sites of FGF2 encompassing the 1, 2, and 11-12 loop-strand regions of the growth factor, 
respectively. The canofin peptides have been demonstrated to specifically bind to FGFR1 and induce 
FGFR1 phosphorylation. Moreover, phosphorylation induced by the cognate ligand, FGF2, is inhibited 
by all three canofins, suggesting that these peptides are partial agonists of FGFR [50]. Canofins 
strongly induce neurite outgrowth from primary cerebellar granule neurons in an FGFR activation-
dependent manner. They have also been shown to be anti-apoptotic, promoting the survival of 
cerebellar granule neurons (Table 1). Canofins are regarded as valuable pharmacological tools for the 
study of the functional roles of specific interactions of FGF2 with FGFR1c [50]. 





In vitro effects  In vivo effects  Refs. 
Canofin1, 





Induction of neurite 
outgrowth by binding to and 
activating FGFR. 
Protection against apoptosis. 
N.D.  [50] Int. J. Mol. Sci. 2010, 11                 
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Binding to and activation of 
FGFR. 
Protection against apoptosis. 
Prolonged retention of social 
memory in adult rats. 
[51,52] 
Hexafin2  6-7 
regions of 
FGFs 
Induction of neurite 
outgrowth by binding to and 
activating FGFR. 
Prolonged retention of social 
memory and decreased anxiety-like 
behavior in adult rats. 
Alleviation of deficits in activity 
related to social behavior, including 
sociability and social novelty, in R6/2 
mouse model of Huntington’s disease. 
[51,52] 
Hexafin3, 




Induction of neurite 
outgrowth by binding to and 
activating FGFR. 
Protection against apoptosis. 
N.D.  [51] 
Hexafin8  6-7 
regions of 
FGFs 
Induction of neurite 
outgrowth by binding to and 
activating FGFR. 
N.D.  [51] 
Dekafin1, 





Induction of neurite 
outgrowth by binding to and 
activating FGFR. 
N.D.  [53] 
Dekafin6, 




Induction of neurite 
outgrowth by binding to and 
activating FGFR. 
Protection against apoptosis. 
N.D.  [53] 
DekaCAM  10-11 
regions of 
FGFs 
Induction of neurite 
outgrowth by binding to and 
activating FGFR. 
N.D.  [53] 
FRM NCAM/ 
FN3(1) 
Stimulation of differentiation 
and neuroprotection. 
N.D.  [56] 
EncaminA NCAM/ 
FN3(1) 
Induction of neurite 
outgrowth by binding to and 
activating FGFR and 
Akt/PKB. 
N.D.  [55] 
EncaminC NCAM/ 
FN3(1) 
Induction of neurite 
outgrowth by binding to and 
activating FGFR and Erk. 
Protection against apoptosis. 
Enhancement of presynaptic 
function. 
N.D.  [55] Int. J. Mol. Sci. 2010, 11                 
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In vitro effects  In vivo effects  Refs. 
EncaminE NCAM/ 
FN3(1) 
Induction of neurite 
outgrowth by binding to and 
activating FGFR and 
Akt/PKB. 
Protection against apoptosis. 
Enhancement of presynaptic 
function. 
N.D.  [55] 
FGL NCAM/ 
FN3(2) 
Induction of neurite 
outgrowth by binding to and 
activating FGFR followed by 
activation of ERK1/2 and 
Akt/PKB. 
Activation of FRS2, ShcA, 
and PLC.  
Protection against apoptosis.  
Promotion of synapse 
formation. 
Enhancement of presynaptic 
function. 
Attenuation of inflammatory 
impact. 
Enhancement of spatial and social 
memory. 
Promotion of postnatal sensorimotor 
development. 
Protection of hippocampal neurons 
against ischemic insult. 
Reduction of neuropathological signs 
and cognitive impairment in 
Alzheimer’s disease model. 
Modulation of the transcriptional 
response to traumatic brain injury. 
Attenuation of age-related changes in 
long-term potentiation and 
inflammatory signs and prevention of 
stress-induced dementia. 
Induction of large changes in the fine 
structure of dendritic spines in the 
hippocampus of aged rats related to 
improved cognitive function. 
Reversal of depression-like 
phenotype in NCAM-deficient 
animals. 
Amelioration of working memory 








Binding to and activating of 
FGFR1.  
Stimulation of neurite 
outgrowth. 
N.D.  [69] 
 
 Int. J. Mol. Sci. 2010, 11                 
 
2297
2.2. Hexafins: Peptide Agonists of FGFR Derived from the 6-7 Loop Regions of Various FGFs 
The hexafin peptides have been identified based on analysis of the structural homology between a 
sequence motif in the second NCAM FN3 module involved in NCAM-FGFR interactions, and the  
6-7 loop region of FGF2 [45]. All 22 FGFs share homologous sequence motifs located in the 6-7 
region [51], and this motif has subsequently been termed the hexafin motif. In the space-filling model 
of FGF2 in Figure 1 the hexafin motif is marked in red in the 6-7 region. This motif is located on 
the FGF2 side opposite to the FGF2-FGFR1c binding interface observed in the crystal structure [49]. 
Hexafins derived from FGF1, 2, 3, 8, 9, 10 and 17 have been characterized and found to bind to 
FGFR1IIIc and FGFR2IIIb, respectively, with kD values ranging from 10
-7 to 10
-8 M. Moreover, these 
peptides have been shown to activate FGFR1-IIIc. Hexafins derived from FGF2, 3, 8, 10, and 17, but 
not from FGF1 and 9, promote neurite extension, and hexafins derived from FGF1, 3, 9, 10, and 17, 
but not from FGF2 and 8, promote neuronal survival [51]. Furthermore, in vivo studies show that 
treatment with hexafin1 and hexafin2 results in prolonged retention of social memory in adult rats, and 
rats treated with hexafin2 exhibit decreased anxiety-like behavior in the elevated plus maze. Hexafin2 
has also been shown to be able to alleviate deficits in activity related to social behavior in the R6/2 
mouse model of Huntington’s disease (Table 1) [52]. 
2.3. Dekafins: Peptide Agonists of FGFR Derived from the β10-β11 Loop Regions of Various FGFs 
The dekafin peptides were identified based on sequence homology between a sequence in the first 
NCAM FN3 module and a sequence motif located in the 10-11 loop regions of all FGFs but FGF19, 
21, 22 and 23 (in human). This motif has subsequently been termed the dekafin motif. Dekafins 
derived from FGF1, 2, 3, 5, 6, 8, 9, 10, and 17 have been characterized and found to bind to 
FGFR1IIIc and FGFR2IIIb, respectively, with kD values ranging from 10
-7 to 10
-8 M [ 52]. Figure 1 
shows the model of FGF2 with the dekafin motif marked in magenta in the 10-11 region. Similar to 
the hexafin motif, the dekafin sequence is located on the FGF2 side opposite to the FGF2-FGFR1 
binding interface observed in the crystal structure [49]. A number of basic residues have been shown 
to be necessary for dekafin1 interactions with FGFR1c. These residues are known to be involved in 
heparin binding, and heparin analogs have been shown to inhibit dekafin1 binding to the receptor [53]. 
Dekafin1, 2, 3, 5, 6, 8, 9, 10, and 17 all induce FGFR1c phosphorylation in TREX cells and neurite 
outgrowth in primary cerebellar granule neurons, although with different potencies. Dekafins are 
partial agonists of FGFR as reflected by their inhibition of receptor activation induced by the cognate 
ligand, FGF1. The neuritogenic effect of dekafin1, 2, and 10 has been shown to be sensitive to 
treatment with a pharmacological inhibitor of FGFR, and dekafin6, 8, 9, and 17 have been 
demonstrated to be neuroprotective in vitro (Table 1). 
3. Peptide Agonists of FGFR Derived from NCAM 
Interactions between NCAM with FGFR occur through binding of the two most membrane-
proximal NCAM modules, FN3 modules 1 and 2. Both NCAM FN3(1) and FN3(2) have been shown 
by surface plasmon resonance analysis to be involved in binding to an Ig2-Ig3 construct of FGFR1 and 
FGFR2, both splice variant IIIc [54]. A number of synthetic peptides have been synthesized based on Int. J. Mol. Sci. 2010, 11                 
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sequence motifs in the FN3 modules of NCAM and been found to interact with FGFR. The peptide 
positions are shown in Figure 2. 
Figure 2. A space-filling model of the two NCAM FN3 modules. Two 180 rotation 
projections are shown. The sequence motifs of EnkaminA, EncaminC, EncaminE, FGL, 
and BCL are mapped in red, blue, yellow, magenta, and cyan, respectively. The figure was 
made using PyMOL Molecular Viewer (DeLano Scientific LLC, San Francisco, CA, USA). 
 
 
3.1. Peptide Agonists of FGFR Derived from the First NCAM FN3 Module 
All FN3 modules have a similar topology. Their tertiary structure is composed of two opposing -
sheets, each containing three to four -strands and the interconnecting loops. To identify peptide 
mimetics with the potential to interact with FGFR, a strand-loop-strand strategy has been used [55]. 
Following this strategy, six peptides sequentially encompassing the AB-, BC-, CD-, DE-, EF-, and FG- 
strand-loop-strand regions have been synthesized and tested for their ability to bind FGFR1 and induce 
FGFR1 phosphorylation. The active peptides derived from the AB-, CD-, and EF-loop regions were 
termed EncaminA, C, and E, respectively [55]. The active peptide derived from the FG-loop region is 
termed dekaCAM [53]. 
EncaminA, C, and E are all located in the C-terminal part of the folded NCAM FN3(1) module. 
They bind to and activate FGFR1. The kD values range from 10
-8 to 10
-7 M. EncaminA and E, but not 
C, activate Akt/PKB, and EncaminE, but not A and C, activates Erk in primary hippocampal neurons. 
EncaminC and E, but not A, have been shown to induce neurite outgrowth and promote the survival of 
cerebellar granule neurons. They also enhance presynaptic function in vitro as reflected by the 
increased rate of transmitter relaese (Table 1) [55]. The Encamin sequence partially overlaps the FRM 
motif, which has been previously shown to be able to stimulate neuronal differentiation and 
neuroprotection [56]. Int. J. Mol. Sci. 2010, 11                 
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3.2. Peptide Agonists of FGFR Derived from the Second NCAM FN3 Module 
The structure of the second NCAM FN3 module has been solved using NMR spectroscopy (as a 
single module [45]) and X-ray crystallography (together with FN3[1]) [46]. One of the FN3(2) strand-
loop-strand regions, the FG loop motif (FGL), has been mapped by NMR titration analysis as an 
NCAM binding site for FGFR [45]. 
The FGL peptide has since been the subject of extensive in vitro and in vivo studies, which have 
established this FGFR agonist as a pharmacological mimetic of various NCAM-related functional 
modalities (Table 1).  FGL has been demonstrated in vitro to bind to and activate FGFR1 and 
downstream signaling molecules and cascades, such as FRS2, ShcA, PLC, Akt/PKB, and Erk1/2 
[57,58], induce differentiation of primary neurons [45,58], promote neuronal survival [58], promote 
synapse formation, enhance presynaptic function [36], and attenuate the impact of inflammation [59]. 
FGL is able to enhance spatial and social memory in normal animals in vivo, promote postnatal 
sensorimotor development [60], protect hippocampal neurons against ischemic insult [61], and 
ameliorate cognitive deficits and reduce neuropathological signs in a model of -amyloid peptide-
induced neurotoxicity, possibly by inhibition of GSK3 [ 62]. Moreover, FGL has been shown to 
modulate the transcriptional response to traumatic brain injury [63], attenuate age-related changes in 
LTP and inflammatory signs [64], and prevent stress-induced dementia, possibly by inducing 
substantial changes in the fine structure of synapses and dendritic spines in the hippocampus [65,66]. 
FGL has also been shown to reverse a depression-like phenotype in NCAM-deficient mice and 
ameliorate working memory deficits in a rat model of schizophrenia [67].  
Importantly, the FGL peptide has been shown to rapidly reach the blood and cerebrospinal fluid 
after systemic administration [60]. FGL has shown no adverse effects in rats, dogs, monkeys 
(preclinical studies), and healthy human male volunteers [68]. Thus, the pharmacological properties of 
FGL indicate that this peptide can target neurodegenerative and cognitive disorders. 
In addition to FGL, peptides derived from other strand-loop-strand regions in the NCAM FN3(2) 
module, namely ABL, BCL, CDL, DEL, and EFL, have been synthesized and tested for their 
capability to bind to FGFR. The BCL peptide was found to be the only peptide that binds to FGFR1 
[69]. Similar to FGL, the BCL peptide has been demonstrated to activate the receptor and induce a 
neuritogenic response. Unlike FGL, however, BCL does not promote neuronal survival [69]. 
4. Concluding Remarks 
Identification of binding sites by structural studies or by in silico molecular modeling allows the 
development of functional agonists or antagonists of cell surface receptors. Thus, peptides derived 
from FGFR binding site of various FGFs and NCAM have been shown to act as agonists of the 
receptor, mimicking the functions of these molecules. The effects of the majority of the peptide 
mimetics presented in Table 1 have been studied using peptides synthesized as dimers or tetramers. A 
dimer or tetramer promote receptor dimerization and thereby activation. However, mimetic peptides 
are usually much less potent than the growth factors from which the peptides are derived. 
Not very surprisingly, a sequence motif engaged in protein-protein interactions observed in a crystal 
structure is capable of mimicking the functional activity of the protein when prepared as a synthetic Int. J. Mol. Sci. 2010, 11                 
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peptide. Examples of such peptides are canofins [49]. Unexpectedly, however, in silico molecular 
modeling has also identified active motifs in FGFs that are located on the side of the growth factors 
that is opposite to the side shown by X-ray crystallography to be involved in receptor binding. 
Examples of such motifs are hexafins and dekafins (Figure 1), whose sequences actually are 
homologous to the canonical binding sites, such as the hexafin and dekafin motifs, see Figure 3. One 
explanation may be that the hexafin and dekafin motifs are remnants of the evolutionary process due to 
gene duplication. However, the hexafin and dekafin peptides show the same receptor binding and 
activation activity as the canofin peptides [51,53]. The non-canonical binding sites in the FGFs may 
also play a role in FGF interactions with FGFR, probably depending on the specific cellular context. 
An alternative explanation may be that the non-canonical binding sites in the FGFs serve to pre-
concentrate the growth factor in close proximity to the FGFRs until it is positioned most favorably for 
high affinity interactions involving the canonical binding sites. Further studies employing FGF2 
mutated on various FGFR binding sites will clarify this issue. 
Figure 3. Sequence of human FGF2 with the canofin1, canofin2, canofin3, hexafin, and 
dekafin motifs marked in blue, green, brown, red, and magenta, respectively. Sequence 
identities are indicated as a percentage of amino-acid overlap. 
 
 
NCAM-FGFR interaction studies reveal multiple binding sites localized on both sides of the 
interface in the vicinity of the contact between the two NCAM FN3 modules (Figure 2). This implies 
that one NCAM molecule might concurrently interact with two FGFR molecules, thus promoting 
receptor dimerization and activation, when NCAM clustering is induced by homophilic NCAM 
adhesion. 
Regardless of the precise roles of multiple FGFR binding motifs in FGFs and NCAM, identification 
of functional FGFR peptide agonists opens new possibilities for the development of pharmacological 
tools to study the molecular mechanisms underlying FGFR activation and signaling. Additionally, 
some of the agonists listed in Table 1 have apparent therapeutic potential. 
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